The purpose of this study was to propose a verification method and results of intensity‐modulated proton therapy (IMPT), using a commercially available heterogeneous phantom. We used a simple simulated head and neck and prostate phantom. An ionization chamber and radiochromic film were used for measurements of absolute dose and relative dose distribution. The measured doses were compared with calculated doses using a treatment planning system. We defined the uncertainty of the measurement point of the ionization chamber due to the effective point of the chamber and mechanical setup error as 2 mm and estimated the dose variation base on a 2 mm error. We prepared a HU‐relative stopping power conversion table and fluence correction factor that were specific to the heterogeneous phantom. The fluence correction factor was determined as a function of depth and was obtained from the ratio of the doses in water and in the phantom at the same effective depths. In the simulated prostate plan, composite doses of measurements and calculations agreed within ±1.3% and the maximum local dose differences of each field were 10.0%. Composite doses in the simulated head and neck plan agreed within 4.0% and the maximum local dose difference for each field was 12.0%. The dose difference for each field came within 2% when taking the measurement uncertainty into consideration. In the composite plan, the maximum dose uncertainty was estimated as 4.0% in the simulated prostate plan and 5.8% in the simulated head and neck plan. Film measurements showed good agreement, with more than 92.5% of points passing a gamma value (3%/3 mm). From these results, the heterogeneous phantom should be useful for verification of IMPT by using a phantom‐specific HU‐relative stopping power conversion, fluence correction factor, and dose error estimation due to the effective point of the chamber.

No abstract

Single-shot measurement of a terahertz field pulse waveform by electro-optic sampling using a chirped optical pulse and a spectrometer was demonstrated by and Jiang and Zhang [Appl. Phys. Lett. 72, 1945 (1998)]. We have performed an experimental and theoretical investigation into the dependence of the waveform thus measured on the chirp rate and spectral resolution. It was found that the waveform exhibits multicyclic behavior at a chirp rate of −0.24 THz2, which corresponds to a chirped-pulse width of over 10 ps, for the monocyclic original terahertz field, while it approaches the monocyclic behavior with decreasing pulse width. Further, broadening of the spectral resolution of the spectrometer gives rise to a monocyclic waveform in the chirp rate range where the waveform is expected to be multicyclic. In addition, we have derived an analytical expression for the terahertz field pulse waveform thus measured without using the method of stationary phase. The theoretical results were found to be consistent with measured ones. Finally, we examined the spectral bandwidth and resolution of terahertz spectroscopy using this method.

The purpose of this study was to provide periodic quality assurance (QA) methods for respiratory‐gated proton beam with a range modulation wheel (RMW) and to clarify the characteristics and long‐term stability of the respiratory‐gated proton beam. A two‐dimensional detector array and a solid water phantom were used to measure absolute dose, spread‐out Bragg peak (SOBP) width and proton range for monthly QA. SOBP width and proton range were measured using an oblique incidence beam to the lateral side of a solid water phantom and compared between with and without a gating proton beam. To measure the delay time of beam‐on/off for annual QA, we collected the beam‐on/off signals and the dose monitor‐detected pulse. We analyzed the results of monthly QA over a 15‐month period and investigated the delay time by machine signal analysis. The dose deviations at proximal, SOBP center and distal points were −0.083 ± 0.25%, 0.026 ± 0.20%, and −0.083 ± 0.35%, respectively. The maximum dose deviation between with and without respiratory gating was −0.95% at the distal point and other deviations were within ±0.5%. Proximal and SOBP center doses showed the same trend over a 15‐month period. Delay times of beam‐on/off for 200 MeV/SOBP 16 cm were 140.5 ± 0.8 ms and 22.3 ± 13.0 ms, respectively. Delay times for 160 MeV/SOBP 10 cm were 167.5 ± 15.1 ms and 19.1 ± 9.8 ms. Our beam delivery system with the RMW showed sufficient stability for respiratory‐gated proton therapy and the system did not show dependency on the energy and the respiratory wave form. The delay times of beam‐on/off were within expectations. The proposed QA methods will be useful for managing the quality of respiratory‐gated proton beams and other beam delivery systems.